The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]
Michael Irizarry, MD, MPH
Advertisement
Senior VP of clinical research, deputy chief clinical officer of the neurology business group, Eisai Ltd
Articles by Michael Irizarry, MD, MPH
The field of Alzheimer disease has entered a new era of earlier detection, creating an opportunity to redefine treatment and the clinical care of patients.
The vice president of Clinical Research at Eisai detailed why lorcaserin’s formula made it suitable for treating patients with Dravet syndrome.
Advertisement
Latest Updated Articles
Michael Irizarry, MD, MPH: Mechanism of Lorcaserin in Dravet SyndromePublished: November 24th 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NeurologyLive® Brain Games: October 26, 2025
2
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
3
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
4
Enhancing Stroke Systems of Care
5
